← Back to patent-cliff list
他达拉非
Tier C — Watch / tradeTadalafil
礼来制药
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PDE5A
Brand：西力士、Cialis、Zalutia、Adcirca、希爱力、PharmFilm <span class="highlightText">Tadalafil</span>
Indications (approved)：前列腺增生、肺性高血压、肺动脉高压、勃起功能障碍
Regional status
US
批准上市
2003-11-21
EU
批准上市
2002-11-12
China
批准上市
2004-01-01
Japan
批准上市
2007-07-31
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tadalafil?
Approved indications include: 前列腺增生, 肺性高血压, 肺动脉高压, 勃起功能障碍.
When does the Tadalafil patent expire?
No public expiry year is available for Tadalafil yet; this page updates once verified.
How do I get a quote for Tadalafil intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25